HUTCHMED (China) Limited
HCMHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong,. The $2.50B market capitalization puts HCM squarely in mid-cap range for its industry. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Market Cap
$2.50B
Beta
0.36
P/E (TTM)
143.60
P/E (Fwd)
55.40
EPS (TTM)
$0.10
EPS (Fwd)
$0.26
ROE
1.5%
ROA
-1.2%
Cash
$1.38B
Total Debt
$94.5M
Free CF
-$18.9M
52W Change
-3.4%
Annual Financials
Cash vs Debt
Where HCM stands vs its 150-day and 200-day moving averages
As of the October 7, 2026 close, HCM finished 14.42% above its 150-day moving average ($12.76) and 10.44% above its 200-day moving average ($13.22). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HCM overbought or oversold?
At the October 7, 2026 close, HCM's RSI(14) was 64.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $1.38B in cash and $94.5M in debt, HCM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$18.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 1.5% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $426.4M to $548.5M.
The relatively low beta of 0.36 suggests HCM is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HCM.